Perspectives on Glucocorticoid treatment of COVID-19: a systematic review
Abstract Coronavirus disease 2019 (COVID-19) is an on-going pandemic, this viral pneumonia can lead to a severe acute respiratory syndrome (SARS). Until the commercialization of a vaccine, pharmacological treatment still represents a great strategy to fight the disease. Glucocorticoids (GC) were widely used in the past coronavirus pandemics and it’s been also used against the SARS-CoV-2. The aim of this study was to review the articles available about the use of GC in patients with COVID-19. In this systematic review randomized or nonrandomized clinical trials and retrospective or prospective controlled longitudinal studies were accepted. Participants could be of any clinical status, geographic location, age and sex. Studies in English, Portuguese and Spanish published since 2019 were included. The focuses of greatest interest were related to length of stay, changes in the radiological profile, viremia and mortality. The research was done electronically on the Pubmed database with the following terms: “corticosteroids”, “glucocorticoids”, “dexamethasone”, “methylprednisolone”, “COVID-19”, “Sars- CoV-2”, “ADRS”. We identified 6,332 publications and at the end 14 were used since they met all inclusion criteria. All of them are retrospective observational studies. These studies included only patients infected with SARS-CoV-2 confirmed by RT-PCR, involving 2,713 participants. The results showed great heterogeneity in their designs and results, which precludes a reliable conclusion on the use of GCs in the treatment of COVID-19..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
ResearchSquare.com - (2022) vom: 29. Juli Zur Gesamtaufnahme - year:2022 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cordeiro, Leonardo P. [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| doi: |
10.21203/rs.3.rs-103178/v1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XRA034719458 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XRA034719458 | ||
| 003 | DE-627 | ||
| 005 | 20230429202123.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220113s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21203/rs.3.rs-103178/v1 |2 doi | |
| 035 | |a (DE-627)XRA034719458 | ||
| 035 | |a (ResearchSquare)10.21203/rs.3.rs-103178/v1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cordeiro, Leonardo P. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Perspectives on Glucocorticoid treatment of COVID-19: a systematic review |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Coronavirus disease 2019 (COVID-19) is an on-going pandemic, this viral pneumonia can lead to a severe acute respiratory syndrome (SARS). Until the commercialization of a vaccine, pharmacological treatment still represents a great strategy to fight the disease. Glucocorticoids (GC) were widely used in the past coronavirus pandemics and it’s been also used against the SARS-CoV-2. The aim of this study was to review the articles available about the use of GC in patients with COVID-19. In this systematic review randomized or nonrandomized clinical trials and retrospective or prospective controlled longitudinal studies were accepted. Participants could be of any clinical status, geographic location, age and sex. Studies in English, Portuguese and Spanish published since 2019 were included. The focuses of greatest interest were related to length of stay, changes in the radiological profile, viremia and mortality. The research was done electronically on the Pubmed database with the following terms: “corticosteroids”, “glucocorticoids”, “dexamethasone”, “methylprednisolone”, “COVID-19”, “Sars- CoV-2”, “ADRS”. We identified 6,332 publications and at the end 14 were used since they met all inclusion criteria. All of them are retrospective observational studies. These studies included only patients infected with SARS-CoV-2 confirmed by RT-PCR, involving 2,713 participants. The results showed great heterogeneity in their designs and results, which precludes a reliable conclusion on the use of GCs in the treatment of COVID-19. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Linhares, Eduarda O.N.N. |e verfasserin |4 aut | |
| 700 | 1 | |a Nogueira, Fernanda G.O. |e verfasserin |4 aut | |
| 700 | 1 | |a Lima, Daniel JM Medeiros |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ResearchSquare.com |g (2022) vom: 29. Juli |
| 773 | 1 | 8 | |g year:2022 |g day:29 |g month:07 |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s43440-021-00225-3 |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21203/rs.3.rs-103178/v1 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XRA | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2022 |b 29 |c 07 | ||